BCRX Annual Cash & Cash Equivalents
$110.64 M
-$194.12 M-63.70%
31 December 2023
Summary:
As of January 22, 2025, BCRX annual cash & cash equivalents is $110.64 million, with the most recent change of -$194.12 million (-63.70%) on December 31, 2023. During the last 3 years, it has fallen by -$161.48 million (-59.34%). BCRX annual cash & cash equivalents is now -78.06% below its all-time high of $504.39 million, reached on December 31, 2021.BCRX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX Quarterly Cash And Cash Equivalents
$96.84 M
+$18.43 M+23.51%
30 September 2024
Summary:
As of January 22, 2025, BCRX quarterly cash and cash equivalents is $96.84 million, with the most recent change of +$18.43 million (+23.51%) on September 30, 2024. Over the past year, it has dropped by -$13.80 million (-12.47%). BCRX quarterly cash and cash equivalents is now -80.80% below its all-time high of $504.39 million, reached on December 31, 2021.BCRX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -63.7% | -12.5% |
| 3 y3 years | -59.3% | -51.5% |
| 5 y5 years | +313.9% | +223.8% |
BCRX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -78.1% | at low | -80.8% | +23.5% |
| 5 y | 5-year | -78.1% | at low | -80.8% | +23.5% |
| alltime | all time | -78.1% | +3997.9% | -80.8% | +5280.1% |
BioCryst Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $96.84 M(+23.5%) |
| June 2024 | - | $78.41 M(-7.0%) |
| Mar 2024 | - | $84.33 M(-23.8%) |
| Dec 2023 | $110.64 M(-63.7%) | $110.64 M(-26.7%) |
| Sept 2023 | - | $150.91 M(+3.2%) |
| June 2023 | - | $146.22 M(-5.8%) |
| Mar 2023 | - | $155.14 M(-49.1%) |
| Dec 2022 | $304.77 M(-39.6%) | $304.77 M(+23.4%) |
| Sept 2022 | - | $246.90 M(-9.4%) |
| June 2022 | - | $272.57 M(-31.1%) |
| Mar 2022 | - | $395.50 M(-21.6%) |
| Dec 2021 | $504.39 M(+85.4%) | $504.39 M(+152.7%) |
| Sept 2021 | - | $199.60 M(-5.1%) |
| June 2021 | - | $210.31 M(-7.3%) |
| Mar 2021 | - | $226.90 M(-16.6%) |
| Dec 2020 | $272.13 M(+138.3%) | $272.13 M(+182.0%) |
| Sept 2020 | - | $96.49 M(-44.4%) |
| June 2020 | - | $173.47 M(+70.3%) |
| Mar 2020 | - | $101.87 M(-10.8%) |
| Dec 2019 | $114.17 M(+327.1%) | $114.17 M(+281.8%) |
| Sept 2019 | - | $29.90 M(-2.8%) |
| June 2019 | - | $30.76 M(-11.6%) |
| Mar 2019 | - | $34.80 M(+30.2%) |
| Dec 2018 | $26.73 M(-46.8%) | $26.73 M(-49.2%) |
| Sept 2018 | - | $52.58 M(+94.0%) |
| June 2018 | - | $27.10 M(-38.1%) |
| Mar 2018 | - | $43.77 M(-13.0%) |
| Dec 2017 | $50.28 M(+127.5%) | $50.28 M(-57.3%) |
| Sept 2017 | - | $117.78 M(+196.7%) |
| June 2017 | - | $39.70 M(-47.2%) |
| Mar 2017 | - | $75.16 M(+240.0%) |
| Dec 2016 | $22.10 M(-23.5%) | $22.10 M(-37.5%) |
| Sept 2016 | - | $35.39 M(+308.6%) |
| June 2016 | - | $8.66 M(-32.9%) |
| Mar 2016 | - | $12.90 M(-55.4%) |
| Dec 2015 | $28.90 M(-47.0%) | $28.90 M(-38.0%) |
| Sept 2015 | - | $46.63 M(-39.3%) |
| June 2015 | - | $76.78 M(+58.7%) |
| Mar 2015 | - | $48.37 M(-11.3%) |
| Dec 2014 | $54.54 M(+157.7%) | $54.54 M(-55.0%) |
| Sept 2014 | - | $121.16 M(-0.3%) |
| June 2014 | - | $121.52 M(+794.6%) |
| Mar 2014 | - | $13.58 M(-35.8%) |
| Dec 2013 | $21.16 M(+1.3%) | $21.16 M(-18.8%) |
| Sept 2013 | - | $26.05 M(+31.8%) |
| June 2013 | - | $19.77 M(+33.5%) |
| Mar 2013 | - | $14.80 M(-29.1%) |
| Dec 2012 | $20.89 M(+27.0%) | $20.89 M(-12.8%) |
| Sept 2012 | - | $23.96 M(+9.3%) |
| June 2012 | - | $21.92 M(-20.7%) |
| Mar 2012 | - | $27.66 M(+68.2%) |
| Dec 2011 | $16.44 M(+20.7%) | $16.44 M(-26.7%) |
| Sept 2011 | - | $22.44 M(+31.9%) |
| June 2011 | - | $17.01 M(-45.7%) |
| Mar 2011 | - | $31.34 M(+130.1%) |
| Dec 2010 | $13.62 M(-66.9%) | $13.62 M(+21.9%) |
| Sept 2010 | - | $11.17 M(-20.3%) |
| June 2010 | - | $14.02 M(-29.5%) |
| Mar 2010 | - | $19.88 M(-51.7%) |
| Dec 2009 | $41.12 M | $41.12 M(+125.6%) |
| Sept 2009 | - | $18.23 M(+32.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2009 | - | $13.81 M(-15.3%) |
| Mar 2009 | - | $16.30 M(-27.0%) |
| Dec 2008 | $22.34 M(-28.3%) | $22.34 M(+40.1%) |
| Sept 2008 | - | $15.95 M(-36.5%) |
| June 2008 | - | $25.14 M(-9.8%) |
| Mar 2008 | - | $27.88 M(-10.5%) |
| Dec 2007 | $31.16 M(+605.3%) | $31.16 M(-29.3%) |
| Sept 2007 | - | $44.09 M(+514.3%) |
| June 2007 | - | $7.18 M(-22.0%) |
| Mar 2007 | - | $9.21 M(+108.4%) |
| Dec 2006 | $4.42 M(-84.8%) | $4.42 M(-42.9%) |
| Sept 2006 | - | $7.73 M(-69.1%) |
| June 2006 | - | $25.05 M(-41.8%) |
| Mar 2006 | - | $43.02 M(+47.5%) |
| Dec 2005 | $29.16 M(+229.9%) | $29.16 M(+220.5%) |
| Sept 2005 | - | $9.10 M(-1.5%) |
| June 2005 | - | $9.24 M(-58.1%) |
| Mar 2005 | - | $22.05 M(+149.5%) |
| Dec 2004 | $8.84 M(+5.9%) | $8.84 M(-36.0%) |
| Sept 2004 | - | $13.81 M(-19.0%) |
| June 2004 | - | $17.05 M(-19.1%) |
| Mar 2004 | - | $21.06 M(+152.3%) |
| Dec 2003 | $8.35 M(-39.6%) | $8.35 M(-22.9%) |
| Sept 2003 | - | $10.83 M(-22.4%) |
| June 2003 | - | $13.95 M(+20.0%) |
| Mar 2003 | - | $11.63 M(-15.9%) |
| Dec 2002 | $13.82 M(-26.7%) | $13.82 M(+2.1%) |
| Sept 2002 | - | $13.54 M(-8.7%) |
| June 2002 | - | $14.83 M(-20.4%) |
| Mar 2002 | - | $18.64 M(-1.2%) |
| Dec 2001 | $18.87 M(+123.1%) | $18.87 M(-2.8%) |
| Sept 2001 | - | $19.40 M(+8.0%) |
| June 2001 | - | $17.96 M(+8.2%) |
| Mar 2001 | - | $16.61 M(+96.4%) |
| Dec 2000 | $8.46 M(-1.7%) | $8.46 M(-3.6%) |
| Sept 2000 | - | $8.77 M(-3.3%) |
| June 2000 | - | $9.07 M(-7.3%) |
| Mar 2000 | - | $9.79 M(+13.8%) |
| Dec 1999 | $8.60 M(-30.1%) | $8.60 M(+38.7%) |
| Sept 1999 | - | $6.20 M(+17.0%) |
| June 1999 | - | $5.30 M(-35.4%) |
| Mar 1999 | - | $8.20 M(-33.3%) |
| Dec 1998 | $12.30 M(+223.7%) | $12.30 M(+151.0%) |
| Sept 1998 | - | $4.90 M(+32.4%) |
| June 1998 | - | $3.70 M(+5.7%) |
| Mar 1998 | - | $3.50 M(-7.9%) |
| Dec 1997 | $3.80 M(+5.6%) | $3.80 M(-32.1%) |
| Sept 1997 | - | $5.60 M(+19.1%) |
| June 1997 | - | $4.70 M(+38.2%) |
| Mar 1997 | - | $3.40 M(-5.6%) |
| Dec 1996 | $3.60 M(-41.0%) | $3.60 M(-44.6%) |
| Sept 1996 | - | $6.50 M(+3.2%) |
| June 1996 | - | $6.30 M(-34.4%) |
| Mar 1996 | - | $9.60 M(+57.4%) |
| Dec 1995 | $6.10 M(+125.9%) | $6.10 M(-53.1%) |
| Sept 1995 | - | $13.00 M(-10.3%) |
| June 1995 | - | $14.50 M(+705.6%) |
| Mar 1995 | - | $1.80 M(-33.3%) |
| Dec 1994 | $2.70 M | $2.70 M(-42.6%) |
| Sept 1994 | - | $4.70 M(+46.9%) |
| June 1994 | - | $3.20 M(-52.2%) |
| Mar 1994 | - | $6.70 M |
FAQ
- What is BioCryst Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is BioCryst Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is BioCryst Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of BCRX is $110.64 M
What is the all time high annual cash & cash equivalents for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high annual cash & cash equivalents is $504.39 M
What is BioCryst Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, BCRX annual cash & cash equivalents has changed by -$194.12 M (-63.70%)
What is BioCryst Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of BCRX is $96.84 M
What is the all time high quarterly cash and cash equivalents for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high quarterly cash and cash equivalents is $504.39 M
What is BioCryst Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, BCRX quarterly cash and cash equivalents has changed by -$13.80 M (-12.47%)